Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.

Saved in:
Bibliographic Details
Title: Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.
Authors: Susanto O; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia., Gruber E; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Wun CM; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Franich RL; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Ma X; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia., Sabouri-Thompson Z; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia., Porter ZJ; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia., Murray HC; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia.; Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, Australia., Cluse LA; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Maher B; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Monash Haematology, Monash Health, Clayton, Australia., Brasacchio D; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia., Martin BP; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Fraser PJ; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Nikolic I; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia., Mir Arnau G; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Molecular Genomics Core, Peter MacCallum Cancer Centre, Melbourne, Australia., Sandow JJ; Walter and Eliza Hall Institute, Parkville, Australia.; Department of Medical Biology, University of Melbourne, Parkville, Australia., Simpson KJ; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Australia., Verrills NM; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia.; Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, Australia., Johnstone RW; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Thompson PE; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia., Kats LM; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Shortt J; Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.; Monash Haematology, Monash Health, Clayton, Australia.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2026 Mar 02; Vol. 25 (3), pp. 416-434.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-25-0306